Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Head & Neck 2Gastrointestinal 2Endocrine 2CNS 2Breast 2Sarcoma 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Breast Neoplasms 4Thyroid Cancer, Papillary 3Sarcoma 3Colonic Neoplasms 3Central Nervous System Neoplasms 3Carcinoma, Medullary 3Wilms Tumor 2Thyroid Neoplasms 2Thyroid Diseases 2Thoracic Neoplasms 2Sarcoma, Ewing 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Respiratory Tract Neoplasms 2Respiratory Tract Diseases 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Neoplasms by Site 2Neoplasms 2Medulloblastoma 2Lymphoma, Non-Hodgkin 2Lung Neoplasms 2Lung Diseases 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Head and Neck Neoplasms 2Glioma 2Ependymoma 2

Interventions

Gemcitabine 5Albumin-Bound Paclitaxel 4130-nm albumin-bound paclitaxel 4selpercatinib 2napabucasin 2entinostat 2Irinotecan 2repotrectinib 1pralsetinib 1pembrolizumab 1lutetium Lu 177 dotatate 1irinotecan sucrosofate 1ganitumab 1copper dotatate CU-64 1Therapeutic Irrigation 1Taxes 1Sunitinib 1Paclitaxel 1Oxaliplatin 1Ocoxin 1Lutetium-177 1Lutetium 1Leucovorin 1Fluorouracil 1Denosumab 1Cisplatin 1Capecitabine 1Blood Specimen Collection 1Ascorbic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Endocrine Gland Neoplasms × selpercatinib × Gastrointestinal × Clear all
NCT03157128 2026-04-16

LIBRETTO-001

Eli Lilly and Company

Phase 1/2 Active not recruiting
857 enrolled 24 charts 3 FDA
BreastCNSEndocrineGastrointestinalHead & NeckThoracic

Thyroid Cancer, Papillary, Breast Neoplasms, Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Head and Neck Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms, Thyroid Diseases, Thyroid Neoplasms, Central Nervous System Neoplasms, Carcinoma, Medullary

NCT03899792 2026-01-06

LIBRETTO-121

Eli Lilly and Company

Phase 1/2 Active not recruiting
36 enrolled 13 charts 2 FDA
BreastCNSEndocrineGastrointestinalHead & NeckSarcomaThoracic

Thyroid Cancer, Papillary, Breast Neoplasms, Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Head and Neck Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Sarcoma, Thoracic Neoplasms, Thyroid Diseases, Thyroid Neoplasms, Central Nervous System Neoplasms, Myofibromatosis, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡